In a report released yesterday, Joshua Schimmer from Evercore ISI maintained a Buy rating on Gossamer Bio Inc (GOSS), with a price target of $30. The company’s shares closed last Monday at $19.43.
According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 11.4% and a 50.6% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Mirum Pharmaceuticals Inc, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Gossamer Bio Inc is a Moderate Buy with an average price target of $30.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.06 and a one-year low of $15.59. Currently, Gossamer Bio Inc has an average volume of 205.6K.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GOSS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions.
